BioMarin Pharmaceutical | BMRN - Assets


BioMarin Pharmaceutical reported $8.59B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 92.5B 1.92B Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026